DRKS00030471招募中不适用
Two-drug antiretroviral therapy with doravirine/dolutegravir - a prospective cohort study - DoDo
Med. Klinik und Poliklinik IV, Sektion Klinische Infektiologie, LMU Klinikum Innenstadt, Ludwig-Maximilians-Universität München0 个研究点目标入组 200 人开始时间: 2022年12月13日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
研究概览
简要总结
DOR and DTG (DoDo) can be a valuable 2DR option also in heavily pretreated people living with HIV. DoDo proved to be both well tolerated and durably potent during about 2639 patient-months of follow-up. More data on this 2-drug-regimen are clearly needed.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Persons being cared for in clinics and private practices in German-speaking areas
- •Age >18 years
- •documented HIV-1-infection
- •documented previous treatment with antiretroviral therapy (ART)
- •switch of ART to exclusively DOR/DTG
- •written informed consent after discussion of patient information
排除标准
- •Inability to consent
- •switch of ART to DOR/DTG in a clinic/practice not participating in the study
- •antiretroviral therapy including other substances except DOR/DTG
研究者
相似试验
已完成
不适用
PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)Infection, Human Immunodeficiency Virus INCT03327740ViiV Healthcare1
Unknown
4 期
Triple vs. Double Therapy in naïves HIV-Infected PatientsHIV InfectionNCT04295460Hospitales Universitarios Virgen del Rocío70
已完成
3 期
DRV/r + RPV QD: Efficacy and Toxicity ReductionHuman Immunodeficiency VirusNCT01792570ASST Fatebenefratelli Sacco37
已完成
不适用
Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive PatientsHIV-1-infectionNCT04002323University Hospital Virgen de las Nieves88
已完成
不适用
Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected ChildrenHuman Immunodeficiency VirusChildrenNCT02285478Radboud University Medical Center12